Logo

CBUS

Cibus, Inc.

CBUS

Cibus, Inc. • NASDAQ
$1.36 ▲ 3.03% (+0.04)
Market Cap $71.68 M
52w High $4.96
52w Low $1.09
Dividend Yield 0%
P/E -0.5
Volume 143.41K
Outstanding Shares 52.71M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $615K ▼ $14.659M ▼ $-23.541M ▲ -3.828K% ▼ $-0.44 ▲ $-14.043M ▲
Q2-2025 $933K ▼ $18.879M ▼ $-25.372M ▲ -2.719K% ▲ $-0.61 ▲ $-16.288M ▲
Q1-2025 $1.034M ▼ $42.605M ▲ $-46.886M ▼ -4.534K% ▼ $-2.02 ▼ $-39.379M ▼
Q4-2024 $1.212M ▼ $19.236M ▼ $-23.102M ▲ -1.906K% ▲ $-0.87 ▲ $-15.913M ▲
Q3-2024 $1.667M $202.104M $-179.968M -10.796K% $-7.63 $-190.914M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $23.886M ▼ $330.226M ▼ $278.197M ▲ $50.401M ▼
Q2-2025 $36.463M ▲ $346.198M ▲ $271.722M ▲ $72.123M ▲
Q1-2025 $23.587M ▲ $335.045M ▼ $261.088M ▲ $70.274M ▼
Q4-2024 $14.433M ▼ $350.069M ▼ $252.238M ▲ $92.157M ▼
Q3-2024 $28.805M $367.874M $246.993M $108.14M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-23.541M ▲ $-11.74M ▲ $-108K ▼ $-725K ▼ $-12.577M ▼ $-11.848M ▲
Q2-2025 $-26.558M ▲ $-13.604M ▼ $-93K ▲ $26.562M ▲ $12.876M ▲ $-13.697M ▼
Q1-2025 $-49.392M ▼ $-11.827M ▲ $-291K ▼ $21.269M ▲ $9.154M ▲ $-12.118M ▲
Q4-2024 $-23.102M ▲ $-13.995M ▼ $-56K ▲ $-306K ▼ $-14.372M ▼ $-14.051M ▼
Q3-2024 $-201.459M $-13.52M $-355K $12.652M $-1.216M $-13.875M

Revenue by Products

Product Q2-2025
Reportable Segment
Reportable Segment
 $0 ▲

Five-Year Company Overview

Income Statement

Income Statement Cibus is still essentially pre‑revenue. Over the past several years it has generated almost no meaningful sales, but it has been consistently spending on operations, leading to recurring losses each year. Those losses look large on a per‑share basis largely because of reverse stock splits, not because of a sudden jump in underlying spending. Overall, the income statement reflects a company that is firmly in the development and commercialization phase, not yet in the revenue‑generating phase.

Balance Sheet

Balance Sheet The balance sheet is very lean. Total assets and cash are modest, with only a small financial cushion relative to its ongoing losses. Debt is present but not very large; however, with such a small asset base, even modest obligations matter. Shareholders’ equity has shrunk over time as losses have accumulated, which is typical for early‑stage biotech, but it also means there is limited balance‑sheet flexibility without additional outside capital.

Cash Flow

Cash Flow Cibus has been consistently burning cash in its day‑to‑day operations, with no offsetting inflows from a mature product line. Capital spending is minimal, so the main cash drain is operating costs such as research, personnel, and overhead. The pattern suggests an early‑stage company that likely depends on capital markets or partners to fund its activities, rather than on internally generated cash.

Competitive Edge

Competitive Edge Cibus operates in a niche within agricultural biotechnology, focused on gene‑editing traits for major crops. Its core edge is a proprietary, high‑throughput gene‑editing platform designed to be faster, more precise, and non‑GMO in regulatory terms. The company aims to license traits to seed companies rather than compete directly in seed production. This positions Cibus as an enabling technology provider with a potentially scalable royalty model, but it also makes it heavily dependent on partners’ willingness and ability to commercialize its traits.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of Cibus. Its Rapid Trait Development System, branded as the “Trait Machine,” is built to rapidly develop and stack multiple traits—such as herbicide tolerance and disease resistance—in crops like rice, canola, soybean, and wheat. The company has a large patent portfolio protecting its methods, and it is actively moving traits toward commercialization, starting with rice herbicide tolerance and expanding into other crops. Future value will hinge on turning this strong research and technology base into widely adopted, revenue‑generating products through successful partnerships and regulatory progress.

Summary

Cibus is a high‑risk, high‑uncertainty, early‑stage agricultural biotech company. Financially, it is pre‑revenue, loss‑making, and cash‑consuming, with a thin balance sheet that underscores its dependence on external funding or partners. Strategically, it has a differentiated gene‑editing platform, robust intellectual property, and a scalable licensing model that together create a meaningful technological moat. The key questions going forward are execution‑related: how quickly and broadly its traits are adopted, how effectively it converts its pipeline into recurring royalties, and how it manages funding needs while navigating regulatory and competitive pressures in agricultural genetics.

NEWS

November 13, 2025 · 4:05 PM UTC

Cibus Reports Third Quarter Financial Results and Provides Year-to-Date Business Update for 2025

Read more

November 11, 2025 · 7:00 AM UTC

Cibus Announces the Election of Craig Wichner to Board of Directors

Read more

October 30, 2025 · 4:05 PM UTC

Cibus to Report Third Quarter 2025 Financial Results on November 13, 2025 After the Market Close and Host Conference Call

Read more

October 16, 2025 · 7:46 AM UTC

Cibus and AgVayā Collaborate to Introduce Indian Rice Growers to New Solutions to Scale Crop Productivity Through Advanced Gene Editing

Read more

October 2, 2025 · 7:00 AM UTC

Cibus Announces Positive Field Trial Results for Second-Generation Herbicide Tolerance (HT2) Edited Canola

Read more